Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease

Cardiovascular Drug Reviews

Volumn 25, Issue 1, 2007, Pages 30-45

  Boerrigter, Guido ^a   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

BAY 41 2272; BAY 58 2667; Blood vessels; Cyclic guanosine monophoshate; Endothelial dysfunction; NO; Soluble guanylate cyclase

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; HMR 1766; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; S 3448; SILDENAFIL; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BINDING SITE; CARDIOVASCULAR DISEASE; CELL GROWTH; CONGESTIVE HEART FAILURE; DISEASE MODEL; DRUG BINDING; DRUG HALF LIFE; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE ADHERENCE; LUNG VASCULAR RESISTANCE; NEONATAL RESPIRATORY DISTRESS SYNDROME; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZOIC ACIDS; CARDIOVASCULAR DISEASES; CELL ADHESION; CYCLIC GMP; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; ENZYME ACTIVATORS; GUANYLATE CYCLASE; HEART FAILURE, CONGESTIVE; HEME; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; INFLAMMATION; LEUKOCYTES; NITRIC OXIDE; PLATELET AGGREGATION; PYRAZOLES; PYRIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; VASODILATOR AGENTS;

EID: 34247282009     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2007.00003.x     Document Type: Review

References (68)

1. Ahluwalia A, Foster P, Scotland RS, McLean PG, Mathur A, Perretti M, Moncada S, Hobbs AJ (2004) Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci U S A 101:1386-1391.
2. Beavo JA, Brunton LL (2002) Cyclic nucleotide research - still expanding after half a century. Nat Rev Mol Cell Biol 3:710-718.
3. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488-520.
4. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, Burnett JC Jr. (2003a) Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 107:686-689.
5. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC Jr (2007) Targeting hemeoxidized guanylate cyclase in experimental heart failure. Hypertension In press.
6. Brunton TL (1867) Use of nitrite of amyl in angina pectoris. Lancet 2:97-98.
7. Castro LR, Verde I, Cooper DM, Fischmeister R (2006) Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 113:2221-2228.
8. Chen Z, Zhang J, Stamler JS (2002) Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A 99:8306-8311.
9. Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, Roy BJ, Keszler M, Kinsella JP (2000). Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 342:469-474.
10. Deruelle P, Balasubramaniam V, Kunig AM, Seedorf GJ, Markham NE, Abman SH (2006) BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol Neonate 90:135-144.
11. Deruelle P, Grover TR, Abman SH (2005a) Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am J Physiol Lung Cell Mol Physiol 289:L798-L806.
12. Deruelle P, Grover TR, Storme L, Abman SH (2005b) Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 288:L727-L733.
13. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, et al. (2006) Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 113:286-295.
14. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, Bloch KD, Zapol WM (2004) Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110:2253-2259.
15. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP (2006) NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5:755-768.
16. Farber HW, Loscalzo J (2004) Pulmonary arterial hypertension. N Engl J Med 351:1655-1665.
17. Fischmeister R, Castro LR, Abi-Gerges A, Rochais F, Jurevicius J, Leroy J, Vandecasteele G (2006) Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 99:816-828.
18. Galle J, Zabel U, Hubner U, Hatzelmann A, Wagner B, Wanner C, Schmidt HH (1999) Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 127:195-203.
19. Gerzer R, Bohme E, Hofmann F, Schultz G (1981) Soluble guanylate cyclase purified from bovine lung contains heme and copper. FEBS Lett 132:71-74.
20. Gryglewski RJ, Palmer RM, Moncada S (1986) Superoxide anion is involved in the breakdown of endotheliumderived vascular relaxing factor. Nature 320:454-456.
21. Hanke CJ, Drewett JG, Myers CR, Campbell WB (1998) Nitric oxide inhibits aldosterone synthesis by a guanylyl cyclase-independent effect. Endocrinology 139:4053-4060.
22. Heck DE, Kagan VE, Shvedova AA, Laskin JD (2005) An epigrammatic (abridged) recounting of the myriad tales of astonishing deeds and dire consequences pertaining to nitric oxide and reactive oxygen species in mitochondria with an ancillary missive concerning the origins of apoptosis. Toxicology 208:259-271.
23. Herrera M, Hong NJ, Garvin JL (2006) Aquaporin-1 transports NO across cell membranes. Hypertension 48:157-164.
24. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS (2005) Protein S-Nitrosylation: purviewand parameters. Nat Rev Mol Cell Biol 6:150-166.
25. Hobbs AJ, Moncada S (2003) Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272. Vascul Pharmacol 40:149-154.
26. Humbert M, Sitbon O, Simonneau G (2004) Treatment of pulmonary arterial hypertension. N Engl J Med 351:1425-1436.
27. Hussain MB, MacAllister RJ, Hobbs AJ (2001) Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases. Am J Physiol Heart Circ Physiol 280:H1151-H1159.
28. John S, Schmieder RE (2003) Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. Curr Hypertens Rep 5:199-207.
29. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM (1994) YC-1, a novel activator of platelet guanylate cyclase. Blood 84:4226-4233.
30. Kuhn M (2003) Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res 93:700-709.
31. Lerman A, Burnett JC Jr. (1992) Intact and altered endothelium in regulation of vasomotion. Circulation 86:III12-III19.
32. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA (2000) Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52:375-414.
33. Madhani M, Okorie M, Hobbs AJ, MacAllister RJ (2006) Reciprocal regulation of human soluble and particulate guanylate cyclases in vivo. Br J Pharmacol 149:797-801.
34. Martin E, Czarnecki K, Jayaraman V, Murad F, Kincaid J (2005) Resonance Raman and infrared spectroscopic studies of high-output forms of human soluble guanylyl cyclase. J Am Chem Soc 127:4625-4631.
35. Masuyama H, Tsuruda T, Kato J, Imamura T, Asada Y, Stasch JP, Kitamura K, Eto T (2006) Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension 48:1-7.
36. McLaughlin VV, McGoon MD (2006) Pulmonary arterial hypertension. Circulation 114:1417-1431.
37. Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A, Verbeuren TJ, Kumar HSA, Schmidt HH (2004) Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci U S A 101:16671-16676.
38. Miller LN, Nakane M, Hsieh GC, Chang R, Kolasa T, Moreland RB, Brioni JD (2003) A-350619: a novel activator of soluble guanylyl cyclase. Life Sci 72:1015-1025.
39. Mullershausen F, Russwurm M, Friebe A, Koesling D (2004) Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. Circulation 109:1711-1713.
40. Mulsch A, Bara A, Mordvintcev P, Vanin A, Busse R (1995) Specificity of different organic nitrates to elicit NO formation in rabbit vascular tissues and organs in vivo. Br J Pharmacol 116:2743-2749.
41. Mulsch A, Bauersachs J, Schafer A, Stasch JP, Kast R, Busse R (1997) Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol 120:681-689.
42. Piggott LA, Hassell KA, Berkova Z, Morris AP, Silberbach M, Rich TC (2006) Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments. J Gen Physiol 128:3-14.
43. Pilz RB, Casteel DE (2003) Regulation of gene expression by cyclic GMP. Circ Res 93:1034-1046.
44. Rocha R, Stier CT Jr., Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK (2000) Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141:3871-3878.
45. Russwurm M, Mergia E, Mullershausen F, Koesling D (2002) Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. J Biol Chem 277:24883-24888.
46. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003) Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93:280-291.
47. Sanchez FA, Savalia NB, Duran RG, Lal BK, Boric MP, Duran WN (2006) Functional significance of differential eNOS translocation. Am J Physiol Heart Circ Physiol 291:H1058-H1064.
48. Sayago CM, Beierwaltes WH (2001) Nitric oxide synthase and cGMP-mediated stimulation of renin secretion. Am J Physiol Regul Integr Comp Physiol 281:R1146-R1151.
49. Schindler U, Strobel H, Schonafinger K, Linz W, Lohn M, Martorana PA, Rutten H, Schindler PW, Busch AE, Sohn M, et al. (2006) Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Mol Pharmacol 69:1260-1268.
50. Schmidt P, Schramm M, Schroder H, Stasch JP (2003) Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur J Pharmacol 468:167-174.
51. Schmidt PM, Schramm M, Schroder H, Wunder F, Stasch JP (2004) Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem 279:3025-3032.
52. Shaul PW, Yuhanna IS, German Z, Chen Z, Steinhorn RH, Morin FC III (1997) Pulmonary endothelial NO synthase gene expression is decreased in fetal lambs with pulmonary hypertension. Am J Physiol 272:L1005-L1012.
53. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T, Perzborn E, Schramm M, Straub A (2002a) Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 135:333-343.
54. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, et al. (2001) NO-independent regulatory site on soluble guanylate cyclase. Nature 410:212-215.
55. Stasch JP, Dembowsky K, Perzborn E, Stahl E, Schramm M (2002b) Cardiovascular actions of a novel NOindependent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol 135:344-355.
56. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss Uet al. (2002). NO- and haem-independent activation of soluble guanylyl cyclase: Molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136:773-783.
57. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Kumar AHS, Meurer S, Deile M, Taye A, Knorr A, Lapp H, et al. (2006) Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116:2552-2561.
58. Straub A, Benet-Buckholz J, Frode R, Kern A, Kohlsdorfer C, Schmitt P, Schwarz T, Siefert HM, Stasch JP (2002) Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase. Bioorg Med Chem 10:1711-1717.
59. Straub A, Stasch JP, Alonso-Alija C, Benet-Buchholz J, Ducke B, Feurer A, Furstner C (2001) NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett 11:781-784.
60. Supaporn T, Sandberg SM, Borgeson DD, Heublein DM, Luchner A, Wei CM, Dousa TP, Burnett JC Jr. (1996) Blunted cGMP response to agonists and enhanced glomerular cyclic 3′,5′-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney International 50:1718-1725.
61. Sydow K, Daiber A, Oelze M, Chen Z, August M, Wendt M, Ullrich V, Mulsch A, Schulz E, Keaney JF Jr. et al. (2004) Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 113:482-489.
62. The Neonatal Inhaled nitric Oxide Study Group (1997) Inhaled nitric oxide in full-termand nearly full-terminfants with hypoxic respiratory failure. N Engl J Med 336:597-604.
63. Valgimigli M, Merli E, Malagutti P, Soukhomovskaia O, Cicchitelli G, Macri G, Ferrari R (2003) Endothelial dysfunction in acute and chronic coronary syndromes: Evidence for a pathogenetic role of oxidative stress. Arch Biochem Biophys 420:255-261.
64. Wagner C, Pfeifer A, Ruth P, Hofmann F, Kurtz A (1998) Role of cGMP-kinase II in the control of renin secretion and renin expression. J Clin Invest 102:1576-1582.
65. Warnholtz A, Mollnau H, Heitzer T, Kontush A, Moller-Bertram T, Lavall D, Giaid A, Beisiegel U, Marklund SL, Walter U, et al. (2002) Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic watanabe rabbits. J Am Coll Cardiol 40:1356-1363.
66. Wilcox CS (2002) Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep 4:160-166.
67. Yuan SY (2006) Newinsights into eNOS signaling in microvascular permeability. Am J Physiol Heart Circ Physiol 291:H1029-H1031.
68. Zanfolin M, Faro R, Araujo EG, Guaraldo AM, Antunes E, Nucci GD (2006) Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J Cardiovasc Pharmacol 47:391-395.